Visugromab in Cachexia International Trial
Public ClinicalTrials.gov record NCT07112196. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Study identification
- NCT ID
- NCT07112196
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 518 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 15, 2026
- Primary completion
- Nov 30, 2029
- Completion
- Nov 30, 2030
- Last update posted
- Aug 30, 2026
2026 – 2030
United States locations
- U.S. sites
- 10
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Eastern Connecticut Hematology & Oncology | Norwich | Connecticut | 06360 | Recruiting |
| Clermont Oncology Center | Clermont | Florida | 34711 | Recruiting |
| Mid Florida Hematology and Oncology Centers | Orange City | Florida | 32763 | Recruiting |
| Cleveland Clinic Martin Health | Stuart | Florida | 34994 | Recruiting |
| Augusta University Medical Center | Augusta | Georgia | 30912 | Recruiting |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | Recruiting |
| Cleveland Clinic Avon Hospital | Avon | Ohio | 44011 | Recruiting |
| Cleveland Clinic (Main Campus) | Cleveland | Ohio | 44195 | Recruiting |
| Cleveland Clinic Fairview Hospital | Fairview | Ohio | 44111 | Recruiting |
| Cleveland Clinic Hillcrest Hospital | Mayfield Heights | Ohio | 44124 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07112196, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07112196 live on ClinicalTrials.gov.